- Home
- GNTA vs ANL Comparison
GNTA vs ANL Comparison
Compare GNTA & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNTA
- ANL
- Stock Information
- Founded
- GNTA 2014
- ANL 2004
- Country
- GNTA Italy
- ANL Cayman Islands
- Employees
- GNTA N/A
- ANL N/A
- Industry
- GNTA Biotechnology: Biological Products (No Diagnostic Substances)
- ANL
- Sector
- GNTA Health Care
- ANL
- Exchange
- GNTA Nasdaq
- ANL Nasdaq
- Market Cap
- GNTA 71.9M
- ANL 79.0M
- IPO Year
- GNTA 2021
- ANL 2023
- Fundamental
- Price
- GNTA $3.96
- ANL $2.25
- Analyst Decision
- GNTA Strong Buy
- ANL Strong Buy
- Analyst Count
- GNTA 1
- ANL 2
- Target Price
- GNTA $25.00
- ANL $9.00
- AVG Volume (30 Days)
- GNTA 5.4K
- ANL 5.8K
- Earning Date
- GNTA 01-01-0001
- ANL 03-04-2025
- Dividend Yield
- GNTA N/A
- ANL N/A
- EPS Growth
- GNTA N/A
- ANL N/A
- EPS
- GNTA N/A
- ANL N/A
- Revenue
- GNTA N/A
- ANL $5,000,000.00
- Revenue This Year
- GNTA N/A
- ANL N/A
- Revenue Next Year
- GNTA N/A
- ANL N/A
- P/E Ratio
- GNTA N/A
- ANL N/A
- Revenue Growth
- GNTA N/A
- ANL N/A
- 52 Week Low
- GNTA $2.20
- ANL $1.85
- 52 Week High
- GNTA $7.28
- ANL $17.48
- Technical
- Relative Strength Index (RSI)
- GNTA 47.29
- ANL 57.33
- Support Level
- GNTA $3.76
- ANL $2.00
- Resistance Level
- GNTA $4.13
- ANL $2.15
- Average True Range (ATR)
- GNTA 0.29
- ANL 0.11
- MACD
- GNTA 0.04
- ANL 0.03
- Stochastic Oscillator
- GNTA 34.29
- ANL 59.52
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.